Get started
Author

Matthias J. Eiber

Observed names: Eiber, Matthias, M Eiber, M. Eiber, Matthias EIBER, Matthias Eiber
Observed institutions: Royal College of Obstetricians and Gynaecologists, University of Bonn, University of California, Los Angeles, The University of Melbourne, University of Würzburg, Queen Elizabeth Hospital Birmingham, University Hospital Bonn, Peter MacCallum Cancer Centre, TUM Klinikum, Queen Elizabeth Hospital, Klinik und Poliklinik für Nuklearmedizin, University Medical Center Hamburg-Eppendorf, Martini-Klinik, Klinik und Poliklinik für Strahlentherapie und Radioonkologie, München Klinik, Universitätsklinikum Würzburg, Deutsches Konsortium für Translationale Krebsforschung, Technical University of Munich, University of Birmingham, Ludwig-Maximilians-Universität München
ORCID: 0000-0003-2654-6872
Observed ORCID: 0000-0003-2654-6872
OpenAlex ID: A5103134027
Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
2015 · Matthias Eiber, Tobias Maurer, et al. · Journal of Nuclear Medicine · 994
Diagnostic Efficacy of 68 Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer
2015 · Tobias Maurer, Jürgen E. Gschwend, et al. · The Journal of Urology · 779
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
2017 · Wolfgang P. Fendler, Matthias Eiber, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 750
Current use of PSMA–PET in prostate cancer management
2016 · Tobias Maurer, Matthias Eiber, et al. · Nature Reviews Urology · 612
Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer
2016 · Matthias Eiber, Gregor Weirich, et al. · European Urology · 568
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
2015 · Martina Weineisen, Margret Schottelius, et al. · Journal of Nuclear Medicine · 532
PDF
Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls
2018 · Michael S. Hofman, Rodney J. Hicks, et al. · Radiographics · 383
Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer
2016 · Thomas Pyka, Shozo Okamoto, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 370
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
2021 · Francesco Ceci, Daniela E. Oprea-Lager, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 366
PDF
Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
2018 · Frederik L. Giesel, Karina Knorr, et al. · Journal of Nuclear Medicine · 334
PDF
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging
2017 · Sara Sheikhbahaei, Ali Afshar-Oromieh, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 296
99mTechnetium-based Prostate-specific Membrane Antigen–radioguided Surgery in Recurrent Prostate Cancer
2018 · Tobias Maurer, Stephanie Robu, et al. · European Urology · 243
Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
2017 · Matthias Eiber, Wolfgang P. Fendler, et al. · Journal of Nuclear Medicine · 241
PDF
Value of 68 Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy
2016 · Isabel Rauscher, Tobias Maurer, et al. · Journal of Nuclear Medicine · 235
PDF
Prostate-specific Membrane Antigen–radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer
2015 · Tobias Maurer, Gregor Weirich, et al. · European Urology · 233
Preclinical Evaluation and First Patient Application of 99m Tc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer
2016 · Stephanie Robu, Margret Schottelius, et al. · Journal of Nuclear Medicine · 228
PDF
PSMA Ligands for PET Imaging of Prostate Cancer
2017 · Sarah M. Schwarzenboeck, Isabel Rauscher, et al. · Journal of Nuclear Medicine · 215
PDF
Radiation Dosimetry for 177 Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
2016 · Shozo Okamoto, Anne Thieme, et al. · Journal of Nuclear Medicine · 212
PDF
68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
2016 · Isabel Rauscher, Tobias Maurer, et al. · Cancer Imaging · 208
PDF
177Lu-PSMA Radioligand Therapy for Prostate Cancer
2017 · Wolfgang P. Fendler, Kambiz Rahbar, et al. · Journal of Nuclear Medicine · 206
The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis
2017 · Martin Barrio, Johannes Czernin, et al. · Journal of Nuclear Medicine · 205
PDF
68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT
2016 · Christina Bluemel, Markus Krebs, et al. · Clinical Nuclear Medicine · 197
Systemic Radioligand Therapy with 177 Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer
2016 · Matthias M. Heck, Margitta Retz, et al. · The Journal of Urology · 187
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
2020 · Edouard J. Trabulsi, R. Bryan Rumble, et al. · Journal of Clinical Oncology · 186
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors
2017 · Charalambos Kaittanis, Chrysafis Andreou, et al. · The Journal of Experimental Medicine · 186
PDF
Works count: 303
Citation count: 15,240
H-index: 63
I10-index: 146
Year
Topic
Type